You can buy or sell Celgene and other stocks, options, ETFs, and crypto commission-free!
Celgene Corporation Common Stock, also called Celgene, is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. Read More The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
Summit, New Jersey
52 Week High
52 Week Low
Why Is Celgene Up 1.4% Since Last Earnings Report?
A month has gone by since the last earnings report for Celgene (CELG). Shares have added about 1.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Celgene due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Celgene Q1 Earnings Beat Estimates on Revlimid Sales Scr...
Yahoo FinanceMay 24
CELG or VRTX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Celgene (CELG) and Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
Seeking AlphaMay 24
Bristol-Myers extends date for exchange offers for Celgene debt to July 8
Bristol-Myers Squibb (NYSE:BMY) has extended the expiration date for its offers to exchange Celgene (NASDAQ:CELG) debt for up to $19.85B of new BMY debt to July 8 from June 3. The amounts of Celgene debt tendered thus far range from 70.65 - 97.79%, depending on the tranche....
$2.43 per share
$2.55 per share